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The number of studies describing methodologies for analysis of cytostatics is very 
limited. The method here described allows the simultaneous determination of 24 
cytostatics and metabolites, the largest number of compounds ever measured with a 
single method. Moreover, to the best of the authors’ knowledge, seven of the 
analytes investigated have never been searched for in the aquatic environment, and 
for many of them the analytical LC-MS/MS conditions, the fragmentation pattern, and 
the stability data provided, would be the first ever published. 
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- 24 compounds from 6 different families were included in the same LC-MS/MS 
method. 
- Fragmentation patterns, most often overlooked in the literature, are provided. 
- Most cytostatics were degraded in water in short periods of time, even at -20ºC. 
- Temperature played an important role on their degradation. 
- Addition of organic solvent improved the stability in water. 
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Abstract 10 
A multianalyte liquid chromatography-electrospray-tandem mass spectrometry (LC-11 
ESI-MS/MS) method for determination of 19 cytostatics and 5 metabolites, from 6 12 
different therapeutic families, has been developed, and the structures of the main 13 
characteristic fragment ions have been proposed. Instrumental limits of detection and 14 
quantification are in the range 0.1-10.3 and 1.0-34.3 ng mL−1, respectively. Moreover, 15 
the stability of the compounds in aqueous solution was investigated in order to 16 
establish the best conditions for preparation and storage of both calibration standards 17 
and water samples. Dimethylsulfoxide (DMSO) was selected as solvent for preparation 18 
of the stock solutions. At room temperature (25 ºC), 11 of the 24 target compounds 19 
were shown to be unstable in water (percentage of organic solvent 4%), with 20 
concentration losses greater than 20% in less than 24 h. At 4 ºC (typical storage 21 
temperature for water samples) all compounds, except MTIC and chlorambucil, were 22 
stable for 24 h, but the number of stable compounds decreased to 10 after 9 days. 23 
Freezing of the aqueous solutions improved considerably the stability of various 24 
compounds: after 3 months of storage at -20 ºC, 10 compounds, namely, 5-fluorouracil, 25 
carboplatin, gemcitabine, temozolomide, vincristine, vinorelbine, ifosfamide, 26 
cyclophosphamide, etoposide, and capecitabine, remained stable (in contrast to only 27 
carboplatin and capecitabine at 4 ºC). The addition of acid improved the stability of 28 
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methotrexate and its metabolite hydroxy-methotrexate but not that of the rest of 29 
compounds. The addition of organic solvent (50% methanol or DMSO) prevented the 30 
degradation at 4 ºC of the otherwise unstable compounds oxaliplatin, methotrexate, 31 
erlotinib, doxorubicin, tamoxifen, and paclitaxel. To the authors’ knowledge, five of the 32 
analytes investigated have never been searched for in the aquatic environment 33 
(imatinib, 6α-hydroxypaclitaxel, endoxifen, (Z)4-Hydroxytamoxifen, and temozolomide), 34 
and for many of them the stability data provided, and even the analytical LC-MS/MS 35 
conditions, are the first ever published. 36 
 37 
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1. Introduction 47 
During recent years great consideration has been given to the contamination of the 48 
environment by veterinary and human pharmaceuticals. Several groups of 49 
pharmaceuticals, such as antibiotics and hormones, have been studied intensively; 50 
however, other potentially more toxic compounds, such as cytostatic agents, have 51 
received very little attention [1]. 52 
 53 
The use of cytostatics for cancer therapy has increased considerably in the last decade 54 
[2, 3], and their production has been estimated to be 5000 kg per year [4]. These 55 
substances act by either inhibiting cell growth or directly killing cells (cytotoxic) [4, 5]. 56 
The reaction mechanisms of cytostatic compounds and their mainly non-specific nature 57 
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of attack within organisms often give rise to secondary side effects and increased 58 
health risks [4]. Thus, many antineoplastic agents have cytotoxic, mutagenic, 59 
carcinogenic, embryotoxic and/or teratogenic effects [1, 4-6]. Recent studies have 60 
reported that persons working with cytostatic drugs, e.g. clinical and pharmaceutical 61 
staff, show a marginally higher frequency of DNA damage. Moreover, they can be 62 
introduced in the environment and even enter the food chain through excretion from 63 
patients under medical treatment as main source [5, 7]. In fact, some of them have 64 
been detected in hospital wastewater at concentration levels varying from ng L-1 to µg 65 
L-1 [8, 9]. 5-Fluorouracil (5-Fu), ifosfamide (IF), and cyclophosphamide (CP) have been 66 
shown to be the most abundant compounds [8, 10-12] but these are also the most 67 
commonly investigated cytostatics. A few works have addressed the study of 68 
doxorubicin (DOX), vincristine (VCN), etoposide (ETP) and methotrexate (MET) [2, 10, 69 
13], which have been found at low concentrations [8]. Martin et al. [14] analysed some 70 
cytostatics not included in previous works, namely, paclitaxel (PAC), irinotecan (IRI), 71 
vinorelbine (VRB), and gemcitabine (GEM), but they were either not detected (PAC 72 
and IRI) or detected at low levels (lower than 10 ng L-1 in influent wastewater) (VRB 73 
and GEM). Recently, the application in a second-phase of the present work of a newly 74 
developed on-line solid phase extraction (SPE)-LC-MS/MS method to the analysis of 75 
13 cytostatics and 4 metabolites in waters, has expanded the list of anti-cancer drugs 76 
measured in environmental samples to 8 new compounds (temozolomide (TMZ), 77 
imatinib (IMA), erlotinib (ERL), capecitabine (CAP), hydroxytamoxifen (OH-TAM), 78 
endoxifen or 4-hydroxy-N-desmethyl-tamoxifen (OH-D-TAM) and hydroxypaclitaxel 79 
(OH-PAC)) and has evidenced for the first time the presence of CAP and OH-PAC in 80 
influent wastewaters at levels up to 30 ng L-1 [15]. Carboplatin has also been detected 81 
in a hospital effluent [7] and, to the authors’ knowledge, other compounds have never 82 
been studied in water samples. 83 
On the other hand, some experimental studies [1, 16-19] have reported genotoxicity in 84 
hospital wastewater effluent samples collected both before and after treatment in 85 
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wastewater treatment plants (WWTPs), but the genotoxicity of pure compounds with 86 
ecotoxicological bioassays has been investigated in only a few occasions [16, 20].  87 
 88 
Most cytostatics are polar compounds often having a high molecular weight, 89 
circumstances that limit the use of gas chromatography (GC) techniques for their 90 
determination since a derivatization step is usually necessary to enhance the volatility 91 
and the thermal stability of the compounds before their injection into the 92 
chromatographic system. Thus, only 5-Fu, TAM, IF and CP have been determined by 93 
GC coupled to mass spectrometry (MS) [11, 21, 22]. Liquid chromatography (LC) 94 
coupled to ultraviolet (UV) detection has been commonly employed for determination of 95 
cytostatics [4, 8, 23]. However, trace-level environmental analysis requires higher 96 
sensitivity, specificity and accuracy, which are only possible using MS detection. The 97 
application of this advanced technique to cytostatics analysis has been described in 98 
some recent works [6, 12, 14, 24-26]. However, many of them focus on the analysis of 99 
just a few classes of cytostatics, and structural information on the product ions chosen 100 
for selected reaction monitoring (SRM) determination has been often overlooked. Only 101 
Gómez-Canela et al. [27] have provided mass spectral characterization for 26 102 
cytostatics, of which, 15 are measured in the present study and 11, namely, TMZ, 5-(3-103 
N-methyltriazen-1-yl)-imidazole-4-carboxamide (MTIC), MET, 5-Fu, VRB, carboplatin 104 
(Carb-Pt), Oxaliplatin (Oxa-Pt) and the metabolites OH-MET, OH-PAC, OH-D-TAM and 105 
OH-TAM, are not.  106 
The number of studies investigating and reporting the presence of cytostatics in water 107 
samples is quite short. This fact can be attributed to either a low medical use or, most 108 
probably, to the existence of degradation processes in the aqueous medium leading to 109 
the transformation of the active principles into other products, which, in turn, can be 110 
more toxic and persistent than the original ones. Little information is known in this 111 
respect, even though some biodegradation products have already been identified. For 112 
example, the biodegradation process of MET is combined with the generation of the 113 
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toxic and persistent degradation product 7-hydroxymethotrexate (OH-MET) [4], TMZ 114 
decomposes to MTIC in the DNA at pH > 7 [28], PAC to OH-PAC, and tamoxifen 115 
(TAM) to OH-TAM and OH-D-TAM. Moreover, low recoveries in the analysis of some 116 
cytostatics in aqueous samples have been reported by some authors [11, 14, 29], 117 
which, in fact, could have their origin in the possible instability of the compounds in the 118 
samples. 119 
In this context, the objectives of this work were: (1) to explore the possibilities of LC-120 
ESI-MS/MS for the analysis of cytostatics by optimizing a multi-analyte method for the 121 
simultaneous determination of 19 anti-cancer drugs and 5 metabolites belonging to 122 
different Anatomical Therapeutic Classification (ATC) classes; (2) to provide 123 
information on their fragmentation pattern, an aspect overlooked in the literature; and 124 
(3) to study their stability and optimum storage conditions in aqueous solution. 125 
 126 
2. Experimental 127 
2.1. Standards and solvents 128 
All solvents were of HPLC grade and all chemicals were of analytical reagent grade. 129 
Formic acid (98-100%), ammonium hydroxide (25%), methanol and HPLC-water were 130 
purchased from Merck (Darmstadt, Germany), while DMSO (DMSO, >99.9%) was 131 
acquired from Aldrich (Milwaukee, WI, USA). 132 
Analytical standards of the cytostatic compounds CAP, Car-Pt, chlorambucil (CHL), 133 
CP, DOX hydrochloride, ERL hydrochloride, ETP, 5-Fu, GEM hydrochloride, IF, IMA 134 
mesylate, MET, OH-MET, MTIC, Oxa-Pt, 6(α)-OH-PAC, TAM citrate, (Z)-4-OH-TAM, 135 
OH-D-TAM, TMZ, vinblastine (VBL) sulfate, VCN sulfate, and VRB ditartrate were 136 
obtained from Santa Cruz Biotechnology (Heidelberg, Germany). Paclitaxel (PAC) was 137 
supplied by Sigma-Aldrich at the highest available purity (>99%). 138 
The selected cytostatics, grouped into six families attending to their mode of action and 139 
chemical structure, are shown in Table 1. 140 
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Individual solutions of each compound (ca. 1000 µg mL-1) and a mixture of them (ca. 141 
25 µg mL-1) were prepared in DMSO and stored in the dark at -20 ºC.  142 
Different working standard solutions were made by appropriate dilution in ultrapure 143 
water, methanol, DMSO or mixtures of them, and were then immediately analyzed by 144 
LC-MS/MS. 145 
 146 
2.2. Safety considerations on cytostatic drugs handling 147 
As cytostatic drugs are highly toxic compounds, their handling requires strict safety 148 
precautions in order to guarantee the best-possible protection of research workers. All 149 
stock solutions were prepared under a biological safety hood with laminar airflow and 150 
an absorbent paper was used to protect the work surfaces. All instruments and 151 
materials that were in contact with tested compounds were disposable and treated as a 152 
hazardous waste. 153 
 154 
2.3. Instrumental and chromatographic conditions  155 
Analyses were carried out using an Acquity UPLC system (Waters, Milford, MA, USA) 156 
consisting of a thermostated autosampler, a binary pump, a vacuum degasser, a 157 
thermostated column compartment and a UV-Vis programmable detector. The UPLC 158 
system was coupled to a Waters TQD triple quadrupole (QqQ) mass spectrometer 159 
equipped with an electrospray ionization (ESI) source. The whole LC–MS/MS system 160 
was controlled by MassLynx 4.1 software (Waters). 161 
Chromatographic separation of the cytostatic drugs was performed on a reversed-162 
phase column Purospher STAR RP-18e (125 x 2 mm, 5 µm particle size) from Merck, 163 
maintained at 25 ºC. Ultrapure water (A) and methanol (B), without modifier or 164 
containing 0.1% of formic acid, were tested as mobile phases. Under final optimized 165 
conditions, compounds were separated with the acidified mobile phase using the 166 
following gradient: 0–1 min, 5% B; 2 min, 20% B; 12 min, 80% B; 19–23 min, 100% B; 167 
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25–30 min, 5% B. The flow rate and the injection volume were set at 0.2 mL min-1 and 168 
10 µL, respectively. 169 
The mass spectrometer was operated using both positive and negative ESI modes 170 
under the following specific conditions: capillary voltage 3.0 kV, extractor voltage 3 V, 171 
source temperature 150 °C, dessolvation temperature 350 °C, cone gas flow 50 L h−1 172 
and dessolvation gas flow 600 L h−1. Nitrogen (>99.98%) was employed as cone and 173 
dessolvation gas. 174 
Detection was accomplished in the selected reaction monitoring (SRM) mode using 175 
argon (>99.999%) as collision-induced dissociation (CID) gas at a pressure of 4 × 10−3 176 
mbar in the collision cell. Selected ionization polarities and optimized MS/MS ion 177 
transitions for each compound are detailed in Table 2. 178 
 179 
3. Results and discussion 180 
 181 
3.1. Chromatographic analysis 182 
In general, the use of tandem mass spectrometry detection reduces the need for 183 
baseline resolution of all analytes, because it is very rare to find molecules with the 184 
same retention time sharing the same unique MS/MS transitions. However, in many 185 
instruments the sensitivity of the MS detector decreases as the number of transitions 186 
recorded increases, and therefore a certain degree of separation is necessary in order 187 
to enable programming of the various SRM transitions into different time windows 188 
along the chromatogram. 189 
Taking into account the different polarities of the studied cytostatics, a reversed-phase 190 
(RP) C18 column was evaluated in an attempt to achieve a suitable separation in the 191 
same chromatographic run. 192 
Different modifiers were tested with the purpose of improving not only the response but 193 
also the peak shape of the compounds. When ammonium acetate (5 mM) was used, 194 
the competitive formation of the corresponding ammonium adducts in the ESI positive 195 
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mode was observed for most of compounds. This finding was in agreement with the 196 
results obtained by Martin [14] & Tuerk [24] for the analysis of ETP and PAC. As most 197 
of the studied compounds are better ionized in the positive mode (Table 2), the use of 198 
this salt as mobile phase modifier was discarded in an attempt to maximize the 199 
ionization efficiency of the protonated molecular ions [M+H]+. 200 
The addition of 0.1% formic acid to the mobile phase improved (approximately 40–201 
60%) the responses of most compounds, especially MET, PAC and the metabolites 202 
OH-MET and OH-PAC, which are hardly observed without acid. This is consistent with 203 
the fact that acidic conditions generally increase positive-ion ESI response (i.e., low pH 204 
conditions favor the formation of the protonated compounds). Nevertheless, the 205 
presence of this acid produced a reduction in the negative ion ESI response of 5-Fu by 206 
about 25%. On the other hand, the positive ion responses of IMA and VRB slightly 207 
decreased with respect to those observed in the absence of modifier, but the peak 208 
shape was considerably improved. So, under optimized conditions, 0.1% formic acid 209 
was added to the mobile phase. 210 
 211 
3.2. Optimization of MS/MS detection conditions 212 
The selection of the specific SRM conditions to achieve maximal sensitivity and 213 
selectivity was performed by injection of individual standard solutions of the 214 
compounds. Table 2 summarizes retention times, most intense SRM transitions, 215 
ionization modes (positive or negative), cone voltages and collision energies (CE) for 216 
target species.  217 
Positive ionization proved to be the most sensitive ionization mode for all the studied 218 
cytostatics, yielding the corresponding protonated parent ion [M+H]+, except for 5-Fu. 219 
The latter could only be ionized in the ESI negative mode, showing the single 220 
negatively charged parent ion [M-H]-.  221 
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Two SRM transitions were selected for each cytostatic (Table 2). The most intense 222 
transition was used for quantification, while the other one was employed for 223 
identification.  224 
 225 
3.3. Fragmentation study 226 
The use of LC-MS/MS for cytostatic analysis is growing. However, structural 227 
elucidation of the product ions selected for their SRM determination is usually missing. 228 
In this work, the fragmentation pattern of each cytostatic considered was investigated. 229 
Fig. 1 shows the corresponding product-ion mass spectra obtained for all studied 230 
compounds, with the chemical structures proposed for each of the resulting fragments. 231 
The strong differences in the chemical structure between the different classes of 232 
anticancer drugs cause also great differences in their fragmentation. In general the 233 
cytostatics belonging to the same group follow a similar mechanism of fragmentation.  234 
For the alkylating agents CP and IF, the most important fragmentation reaction under 235 
the selected conditions was the cleavage of the N-P bond leading to the formation of 236 
the ions m/z 140 and 120 for CP, and 183, 155 and 92 for IF, as it has been previously 237 
reported [12]. The main fragments of CHL are at m/z 192, due to the loss of two 238 
molecules of CH4Cl, and at m/z 168, due to the loss of CH4Cl and C3H5O2. For MTIC 239 
the most intense ions are at m/z 109 and 126; and for TMZ at m/z 138 and 82. 240 
MET and its metabolite OH-MET form fragments at m/z 308 and 324, respectively, due 241 
to the loss of m/z 148 (C5H10NO4). The pyrimidine analogue 5-Fu breaks its ring 242 
yielding fragments at m/z 86 (C2H2N2O2
-) and m/z 42 (CNO-). The loss of the 243 
tetrahydrofuran ring with their substituents of the GEM and CAP molecules gives 244 
product ions at m/z 112 and 244, respectively, data not found in the literature. 245 
The group of the vinca alkaloids, VBL, VCN, and VRB, with parent ions of 812, 826, 246 
and 780, respectively, break in very small fragments. VBL and VRB lose, initially, an 247 
acetyl group and give fragments at m/z 751 and 658, respectively. VCN loses a 248 
molecule of H2O (18 uma) and gives the fragment at m/z 807. Then, the compounds’ 249 
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rings break forming ions at m/z 224, 138 and 323 for VBL, VCN, and VRB, 250 
respectively. 251 
ETP fragments at m/z 229 and 185. The first one is due to the loss of the glycoside and 252 
the dimethoxyphenol rings and formation of two double bonds in the central molecule. 253 
In addition, the last molecule losses the dioxolane ring and gives the m/z 185. 254 
The taxanes PAC and OH-PAC give two main fragments at m/z 569 and 286 in the 255 
case of PAC and at m/z 525 and 286 in the case of OH-PAC due to the breakdown of 256 
the ester into two molecules and the formation of a double bond. 257 
DOX losses the glycoside portion and gives a product ion at m/z 397, and with a further 258 
loss of two water molecules leads to a product ion of m/z 361. The transitions from m/z 259 
544 to 361 and from m/z 544 to 397 were used in our SRM analysis [6]. 260 
The fragments of Car-Pt and Oxa-Pt are difficult to elucidate, though some structures 261 
are proposed. 262 
The two protein kinase inhibitors (IMA and ERL) undergo different mechanisms of 263 
fragmentation. IMA gives two fragments at m/z 394 and 99 due to the formation of a 264 
double bond between the unshared pair of nitrogen belonging to the piperazine ring 265 
with the piperazine ring, and the subsequent breakdown of the molecule. The fragment 266 
at m/z 217 corresponds to the rupture of the bond between N and C of the amide and 267 
formation of an aldehyde group. ERL fragments at m/z 336 and 278 are due to the loss 268 
of one and two substituents C3H7O remaining one and two hydroxyl groups, 269 
respectively. 270 
The anti-estrogens TAM and their metabolites (OH-TAM and OH-D-TAM) break down 271 
in very small fragments. TAM and OH-TAM share the same product ions at m/z 72 and 272 
m/z 45, which correspond to imines. 273 
 274 
 275 
 276 
 277 
 11 
3.4. Method performance 278 
 279 
Fig. 2 illustrates the analysis of the target compounds, which were separated in 30 min. 280 
In order to improve the limits of detection (LOD) and quantification (LOQ), they were 281 
grouped into 11 segments according to their elution order. The total dwell time per 282 
segment was maintained at 1.2 s. The dependence between peak areas and analytes 283 
concentration was investigated with standards prepared in HPLC water (maximum 284 
percentage of DMSO 4%) at 7 different concentrations in the range from 5 to 2000 ng 285 
mL−1 (injection volume 15 µL). Most compounds gave a linear response in the above 286 
range, with determination coefficients (R2) between 0.9917 and 0.9996, whereas MTIC 287 
and CHL showed R2 values of 0.7481 and 0.9776, respectively, because they were not 288 
stable under those conditions (see Table 3). Instrumental LODs, defined for a signal to 289 
noise ratio (S/N) of 3, varied between 0.1 and 10.3 ng mL−1, whereas the LOQs (S/N = 290 
10) were in the range 1.0 - 34.3 ng mL−1. The repeatability in the responses of the 291 
system was evaluated with standards at two different concentrations: 50 and 200 ng 292 
mL−1. Relative standard deviations (RSDs, %) for 5 injections made in the same day 293 
ranged from 0.3 to 6.1%, if MTIC (RSD = 30.2 - 32.9%) and CHL (RSD = 20.6 – 294 
33.3%) are excluded. 295 
 296 
3.5. Stability of cytostatics 297 
 298 
The fact that some compounds did not present linearity and had relatively large RSDs 299 
induced us to think that they were not stable in aqueous solution. Moreover, low 300 
recoveries in the analysis of some cytostatics in water samples have been reported by 301 
some authors, which could be also due to stability problems. In this context, one 302 
purpose of this work was to study the stability of the 24 target cytostatics and 303 
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metabolites in aqueous solutions and in organic solvents in order to establish the best 304 
conditions for preparation and storage of both calibration solutions and water samples. 305 
 306 
3.5.1. Effect of the temperature 307 
 308 
The first aspect investigated in this respect was the short-term stability of the 309 
compounds in water at different temperatures. For this purpose HPLC-water was 310 
spiked with the target compounds at 1 µg mL-1 (percentage of DMSO 4%) and was 311 
injected in the HPLC system immediately after preparation and every 30 min within the 312 
next 24 hours. During this period, the solution was maintained protected from light at 313 
different constant temperatures: 4, 15 and 25 ºC. The selection of these temperatures 314 
was based on the following premises: 4 ºC is the temperature at which most 315 
laboratories store water samples from collection to analysis; 25 ºC was selected as 316 
room temperature, and it is also a temperature used in multiple laboratory exposure 317 
experiments, and a temperature that can be reached in Southern European rivers in 318 
summer; and 15 ºC was selected as an intermediate value between the other two, 319 
expected to be close to the annual average water temperature of most European 320 
rivers. Table 4 shows the percentage of each compound that remained in solution after 321 
24 h at the three studied temperatures. As it can be seen, at 4 C most compounds 322 
were stable, with relative responses within the range 100 ± 20%. The only compounds 323 
that showed clearly lower peak signals after 24 h, as compared to the peak signals at 324 
time zero, were MTIC (12%) and CHL (20%). Meanwhile, at higher temperatures a 325 
reduction of the initial peak signal with time was evident for about half of the 326 
compounds investigated and, as expected, the signal decay increased with 327 
temperature. At 25 C, 12 of the 24 compounds tested, namely, 5-Fu, GEM, TMZ, 328 
VCN, VBL, VRB, IF, CP, ERL, ETP, CAP, and OH-PAC, were stable (relative response 329 
above 80%) for 24 h; 6 compounds, namely, Car-Pt, IMA, DOX, OH-D-TAM, OH-TAM, 330 
and PAC showed some degradation, with relative responses within the margin 50 to 331 
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80%; and the remaining 6 compounds, namely, Oxa-Pt, MET, MTIC, OH-MET, TAM, 332 
CHL, were degraded to a large extent, with relative responses below 50% (in fact, the 333 
last three compounds were not detected after 24 h at both 25 and 15 C). 334 
In the light of these results, the stability of the compounds at 4 ºC was studied during a 335 
longer period of time by analysing sample aliquots every day during the first 9 days and 336 
after 1, 2 and 3 months of storage in the dark at this temperature. Fig. 3 shows that 337 
after 9 days the amount of 11 of the target compounds, namely, Oxa-Pt, MET, its 338 
metabolite OH-MET, VBL, IMA, ERL, DOX, TAM, its metabolite OH-D-TAM, PAC, and 339 
its metabolite OH-PAC, decreased substantially (to around 50%), MTIC and CHL 340 
disappeared completely already after 3 days, and the remaining compounds (5-Fu, 341 
Car-Pt, GEM, TMZ, VCN, VRB, IF, CP, ET, CAP, and OH-TAM) were stable (relative 342 
response above 80%). After 1 month, all the compounds that were shown to be stable 343 
for 9 days, with the exception of OH-TAM, stayed stable (see Fig. 4), whereas after 3 344 
months only Car-Pt and CAP remain unaltered. 345 
These results are in line with those previously published by other authors. Very 346 
recently, Tuerk et al. [24], reported recoveries of about 40 and 70% for PAC and 347 
docetaxel (another cytostatic that belongs to the family of the taxanes), respectively, in 348 
tissues used to wipe sampling areas in pharmacies, and further wetted with 1 mL 349 
phosphate buffer and stored at room temperature for 48 hours and at -18 ºC for 7 days. 350 
They studied also other cytostatics, namely, 5-Fu, GEM, MET, CP, IF, and ETP, but 351 
recovery rates were closer to 100%. Sottani et al. [6] studied the stability of CP, IF and 352 
DOX in human urine, and found that all of them were stable (concentration measured 353 
equal to the initial concentration ± 20%) for at least 8 hours at room temperature and 354 
for 15 days at -20 ºC. Chen et al. [23] found that 5-Fu and PAC were stable in samples 355 
of drug-coeluting stents prepared in 15 mL of phosphate-buffered saline (PBS) (pH 7.4; 356 
0.05 M, 1% sodium dodecyl sulfate) for at least 24 hours at room temperature (which is 357 
in line with our results) and for 1 month at 4 ºC (when in our experiment PAC 358 
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decreased in concentration more than 50% after 3 days of storage at the same 359 
temperature (4 ºC)). 360 
Since about half of the compounds were observed to be unstable at 4 ºC after various 361 
days, freezing at -20 ºC was evaluated as a possible means to store and preserve both 362 
water samples and calibration solutions. For this purpose, samples of HPLC-water 363 
spiked with the target compounds at 1 µg mL-1 and stored in the dark at -20 ºC were 364 
analysed after different storage times (3 days, 9 days, and 1, 2 and 3 months) and 365 
compared with a sample prepared in the same way and analysed immediately after. As 366 
it can be seen in Fig. 5, freezing improved considerably the stability of various 367 
compounds in water. After 3 months of storage at -20 ºC, 10 compounds, namely, 5-368 
Fu, Car-Pt, GEM, TMZ, VCN, VRB, IF, CP, ETP, and CAP, remained stable, in contrast 369 
to only Car-Pt at 4 ºC. Freezing for 1 month would be suitable for the above mentioned 370 
10 compounds plus Oxa-Pt and OH-D-TAM, i.e. for 12 of the 24 target compounds, 371 
whereas at 4 ºC only 10 compounds were stable for 1 month. Between 1 month and 9 372 
days the differences are minimal: the only compounds unstable for 1 month but stable 373 
for 9 days were MET, OH-MET, and OH-TAM; hence, the number of compounds stable 374 
at -20 ºC for 9 days is 15. Finally, storage at -20 ºC for 3 days would be acceptable for 375 
all but 7 compounds (MTIC, IMA, ERL, DOX, OH-PAC, PAC, and CHL), which are not 376 
stable either under these conditions. 377 
These findings are in agreement with those of Nussbaumer et al. [30] who studied the 378 
stability of some cytostatics (cytarabine, GEM, MET, ETP, CP, IF, IRI, DOX, EPI and 379 
VCN) on filter papers over 3 months at three storage temperatures (-20, 4 and 25 ºC). 380 
They found that at 25 ºC only IF was stable for 3 months. Concentrations of ETP, DOX, 381 
EPI and VCN were already decreased to 20% after 1 week. At 4 ºC, the wiping 382 
samples were stable for 1 week. After 2 months, the concentrations of DOX, EPI and 383 
VCN were inferior to 50% of the initial amount, and at 3 months 50% of ETP was lost. 384 
The other compounds were stable for 3 months at 4 ºC. At -20 ºC all drugs tested were 385 
stable for 2 months. 386 
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Osawa et al. [31] validated a method for the determination of the contamination of the 387 
exterior surface of vials containing platinum anticancer agents (cisplatin and 388 
carboplatin) and found that stock solutions of cisplatin and carboplatin prepare in saline 389 
solution and ultra-pure water, respectively, were stable at 4 ºC for at least 3 months, 390 
which is in agreement with our results. 391 
 392 
3.5.2.Effect of the addition of acid 393 
 394 
The effect of addying acid to the water samples as a preservation method was 395 
subsequently investigated by using HPLC-water spiked with the analytes (same 396 
concentration as above, 1 µg mL-1) and formic acid (0.1%). This solution was 397 
maintained in the dark at 4 ºC and injected every day during 9 days. Fig. 6 shows 398 
comparatively the results obtained for the various compounds in the ninth day with and 399 
without acid. As it can be seen the behaviour was very variable. Most compounds 400 
showed similar results with and without acid. MET and its metabolite OH-MET, 401 
compounds that without acid decreased in concentration to about 60 and 40%, 402 
respectively, were stable after 9 days when acid was added. MTIC decreased in 403 
concentration in both cases, but its degradation in the acidified sample was much less 404 
pronounced (60% versus nearly 100% in the non-acidified sample). In contrast, other 405 
compounds like IMA, TAM, and its metabolite OH-TAM were even less stable in the 406 
presence of acid. Therefore, the addition of acid would only be a solution for MET and 407 
its metabolite, not for the rest of compounds. 408 
 409 
3.5.3.Effect of the addition of organic solvent 410 
 411 
Another factor that could improve the stability of sparingly water soluble species is the 412 
addition of a miscible organic solvent. This effect was studied with methanol and 413 
DMSO. For this purpose standard solutions containing the mixture of the target 414 
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compounds at 1 µg mL-1 were prepared in DMSO:water 4:96, DMSO:water 50:50 and 415 
methanol:water 50:50 and were injected daily during 9 days. The peak shape got 416 
worse when the percentage of organic solvent increased but the peak areas obtained 417 
could still be used to compare and establish the best conditions for preparation and 418 
storage of standard solutions and water samples. Fig. 7 shows the results obtained 419 
after 3 and 9 days of storage at 4 ºC. This figure does not include those compounds 420 
that were observed to be stable in 4% DMSO. Moreover, the metabolites OH-TAM, 421 
OH-D-TAM, OH-MET and OH-PAC are not represented because they follow the same 422 
behaviour as their parent compounds. Hence, in Fig. 7 we can observe the behaviour 423 
of Oxa-Pt, MTIC, MET, VBL, IMA, ERL, DOX, TAM, PAC, and CHL. Oxa-Pt, MET, 424 
ERL, DOX, TAM, and PAC resulted to be stable in 50% of organic solvent (DMSO and 425 
methanol) and no major differences were observed between the third and the ninth 426 
days of storage. Meanwhile, the rest of compounds were degraded to a different 427 
extent, and MTIC and CHL were again the least stable compounds. However, the 428 
degradation increased when the percentage of organic solvent was lower (4%). Hence, 429 
it is clear that the presence of water in the solution plays an important role. 430 
 431 
3.5.4.CHL and MTIC 432 
 433 
Among all analytes investigated CHL and MTIC stand out clearly as the most unstable 434 
compounds. 435 
CHL is a chemotherapy drug that has been mainly used in the treatment of chronic 436 
lymphocytic leukemia. It is a nitrogen mustard alkylating agent and can be given orally. 437 
It has also been associated with the development of other forms of cancer [4]. 438 
However, to the best of our knowledge, this compound has not been investigated in the 439 
aquatic environment and there are no data about its presence or its stability in it. 440 
Hence, this compound was studied further in more detail. 441 
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When prepared in HPLC-water, this compound was observed to completely disappear 442 
after only half an hour at room temperature, and this was accompanied by the 443 
appearance of a new chromatographic peak at a lower retention time (6.2 min). The 444 
mass spectrum of the newly formed compound obtained in the ESI positive mode 445 
exhibited a [M+H]+ ion at m/z 269, corresponding to the loss of a chlorine atom from the 446 
CHL molecule. Its capillary voltage, collision energy and MS/MS transitions were 447 
optimized and the most intense fragment was observed at m/z 192, the same as CHL. 448 
The second most intense fragment was found at m/z 132. 449 
In order to establish whether this product was stable and how much time was 450 
necessary for a total conversion, CHL was spiked in HPLC-water at 1 µg mL-1 (4% 451 
DMSO) and this solution was injected immediately after and at different time intervals 452 
during the following 8 days while maintained at different temperatures (4, 15 and 25 453 
ºC). Under these conditions, CHL disappeared quickly and the new compound, without 454 
a chlorine atom, was formed. Between 15 and 25 ºC there were no differences, but at 4 455 
ºC the subproduct was formed in a comparatively minor extension.  456 
Fig. S1 (in the Supplementary Information) shows that the response of the subproduct 457 
increased with time up until the equilibrium was reached (which at 4 ºC occurred after 458 
120 hours), remaining stable thereafter for at least 4 more days. 459 
A similar behaviour was also observed for MTIC. This compound is a 460 
pharmacologically active hydrolysis product of TMZ [28], but our results indicate that 461 
MTIC is less stable than TMZ. Fig. S2 (Supplementary Information) shows how MTIC is 462 
quickly degraded, remaining only 1% of the compound after 3 and 4 hours at 25 and 15 463 
ºC, respectively. The degradation at 4 ºC is slower than at the other temperatures 464 
studied and after 3 hours 30% of the compound remained in solution. 465 
 466 
4. Conclusions  467 
An LC-MS/MS method has been developed for the analytical determination of 19 468 
cytotoxic drugs and 5 transformation metabolites at the low ng mL-1 level. Their stability 469 
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in water has been studied under different conditions (in relation with temperature, 470 
addition of acid, and addition of organic solvent) over 3 months, constituting for many 471 
of them the first study of these characteristics carried out. All compounds with the 472 
exception of Car-Pt have been shown to be degraded to a higher or lower extent when 473 
stored in aqueous solution for a certain time, which may vary from hours to months 474 
depending on the temperature (see Table 5). Hence, stock standard solutions shall be 475 
prepared in pure organic solvent and the aqueous calibration solutions shall be made 476 
up immediately before use. Since some compounds are not readily soluble in methanol 477 
(e.g. Oxa-Pt and GEM) and some may also undergo hydrolysis and transesterification 478 
in this solvent (e.g. PAC) [32], DMSO appears as a suitable solvent for preparation of 479 
stock standard solutions. DMSO presents a high capacity to dissolve substances 480 
without interacting with them and is miscible with water. Nevertheless, since DMSO 481 
has a relatively high freezing point (18.5°C) and hence it is solid at, or just below, room 482 
temperature, precaution should be taken at not injecting a pure 100% DMSO standard 483 
solution directly into the HPLC system. 484 
On the other hand, the fact that many compounds are unstable in water may be behind 485 
the lack of studies on cytostatics in water. The inherent instability associated with some 486 
compounds makes their quantification extremely difficult in aqueous matrices and this 487 
may explain the absence of published data on validated quantitative analytical methods 488 
for the determination of many of them. Further studies should investigate the possible 489 
transformation of these compounds into other products, their potential environmental 490 
effects, and the eventual risks to humans from environmental exposure to these 491 
substances. To this end, the application of the LC-MS/MS method developed to the 492 
analysis of environmental samples may be of help, though a previous stage of pre-493 
concentration is necessary. 494 
 495 
 496 
 497 
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Captions to figures 572 
Fig. 1. Product-ion mass spectra obtained for each of the target compounds in the ESI 573 
positive mode and corresponding suggested structures. 574 
Fig. 2. SRM chromatograms obtained from the analysis of a standard mixture in HPLC-575 
water at 100 ng mL-1 by LC-ESI-MS/MS. 576 
Fig. 3. Stability data of the target cytostatic compounds and metabolites in HPLC water 577 
(initial concentration 1 µg mL-1) stored at 4 ºC for 9 days. 578 
Fig. 4. Relative response of the most stable cytostatic compounds and metabolites in 579 
HPLC water (initial concentration 1 µg mL-1) after 1, 2, and 3 months of storage at 4 ºC. 580 
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Fig. 5. Stability data of the target cytostatic compounds and metabolites in HPLC water 581 
(initial concentration 1 µg mL-1) stored at -20 ºC for different time periods up to 3 582 
months. 583 
Fig. 6. Effect of the addition of formic acid on the stability of the compounds in water 584 
after storage for 9 days.  585 
Fig. 7. Effect of the addition of organic solvent on the stability of the compounds in 586 
water stored at 4 ºC for 3 and 9 days.  587 
Table 1 
Abbreviated names, molecular mass, acid-base dissociation constant (pKa), octanol-water 
partition coefficient (log Kow), and ATC group of the target cytostatics. 
Compound (acronym) 
Molecular  
Mass 
b
pKa 
b
log KOW Group 
ALKYLATING AGENTS 
Cyclophosphamide (CP) 260.02 2.84 0.73 
Nitrogen mustard 
analogues 
Ifosfamide (IF) 260.02 1.44 0.78 
Nitrogen mustard 
analogues 
Chlorambucil (CHL) 304.21 
4.82 (acidic) 
4.62 (basic) 
2.61 
Nitrogen mustard 
analogues 
Temozolomide (TMZ) 194.20 
14.77 (acidic) 
-1.63 (basic) 
-1.27 
Other alkylating 
agents 
a
 MTIC 168.16 
10.07 (acidic) 
2.23 (basic) 
-1.16 
Other alkylating 
agents 
ANTIMETABOLITES 
Methotrexate (MET) 454.45 
3.47 (acidic) 
5.56 (basic) 
-0.45 Folic acid analogues 
a
 Hydroxymethotrexate 
(OH-MET) 
470.44 
3.48 (acidic) 
4.99 (basic) 
-0.69 Folic acid analogues 
5-Fluorouracil (5-FU) 130.02 - -0.65 Pyrimidine analogues 
Gemcitabine (GEM) 299.66 
11.65 (acidic) 
4.26 (basic) 
-2.22 Pyrimidine analogues 
Capecitabine (CAP) 359.15 
5.41 (acidic) 
1.75 (basic) 
1.04 Pyrimidine analogues 
PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS 
Vinblastine (VBL) 810.97 
11.36 (acidic) 
7.90 (basic) 
5.92 
Vinca alkaloids and 
analogues 
Vincristine (VCN) 824.96 
11.10 (acidic) 
7.90 (basic) 
5.75 
Vinca alkaloids and 
analogues 
Vinorelbine (VRB) 778.93 
11.36 (acidic) 
6.90 (basic) 
7.08 
Vinca alkaloids and 
analogues 
Etoposide (ETP) 588.57 
9.94±0.40 
(acidic) 
0.28 
Podophyllotoxin 
derivatives 
Paclitaxel (PAC) 853.91 
11.90 (acidic) 
-2.19 (basic) 
3.95 Taxane 
a
 6(α)-Hydroxypaclitaxel 
(OH-PAC) 
869.91 
11.90 (acidic) 
-2.19 (basic) 
3.19 Taxane 
CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES 
Doxorubicin (DOX) 543.52 
7.35 (acidic) 
8.68 (basic) 
1.27  
Anthracyclines and 
related substances 
OTHER ANTINEOPLASTIC AGENTS 
Carboplatin (Car-Pt) 371.25 - -2.19 Platinum compounds 
Oxaliplatin (Oxa-Pt) 397.29 - -1.67 Platinum compounds 
Imatinib (IMA) 493.60 
13.28 (acidic) 
7.55 (basic) 
2.89 
Protein kinase 
inhibitors 
Erlotinib (ERL) 393.44 5.32 3.03 
Protein kinase 
inhibitors 
HORMONE ANTAGONISTS AND RELATED AGENTS 
Tamoxifen (TAM) 371.51 8.69 5.13 Anti-estrogens 
a
 4-Hydroxy-N-desmethyl-
tamoxifen or Endoxifen 
(OH-D-TAM) 
373.49 
9.38 (acidic) 
9.34 (basic) 
4.94 Anti-estrogens 
a
 (Z)-4-Hydroxytamoxifen 
(OH-TAM) 
387.51 
10.35 (acidic) 
8.70 (basic) 
4.93 Anti-estrogens 
a 
active metabolite 
b
 Values obtained from SciFinder Scholar Database, http://www.cas.org/products/sfacad/. 
Table(s)
Table 2 
LC retention time (tR) and selected MS/MS detection conditions for determination of the target 
cytostatics. 
Compound tR
 
(min) Seg.
a
 Ionization Parent ion 
MS/MS 
 Transition
 b Cone (V) CE (eV)
 c
 
5-FU 3.25 1 ESI- [M-H]
-
 
129.0 > 42.0 30 15 
129.0 > 86.0 30 15 
Car-Pt 3.25 2 ESI+ [M+H]
+
 
372.0 > 355.0 25 10 
372.0 > 294.0 25 20 
GEM 3.82 3 ESI+ [M+H]
+
 
264.0 > 112.0 30 15 
264.0 > 95.0 30 45 
Oxa-Pt 4.03 3 ESI+ [M+H]+ 
398.0 > 96.0 40 25 
398.0 > 308.0 40 20 
MTIC 4.05 3 ESI+ [M+H]
+
 
169.0 > 109.0 10 5 
169.0 > 124.0 10 5 
TMZ 4.69 4 ESI+ [M+H]
+
 
195.0 > 138.0 25 10 
195.0 > 82.0 25 20 
MET 6.49 5 ESI+ [M+H]
+
 
455.0 > 308.0 20 20 
455.0 > 175.0 20 35 
OH-MET 8.00 6 ESI+ [M+H]
+
 
471.2 > 324.2 20 10 
471.2 > 191.0 20 20 
VCN 8.71 7 ESI+ [M+H]
+
 
825.6 > 138.0 50 40 
825.6 >807.0 50 45 
VBL 9.13 8 ESI+ [M+H]
+
 
811.6 > 751.0 50 45 
811.6 > 224.0 50 45 
VRB 9.54 8 ESI+ [M+H]
+
 
779.6 > 658.0 40 25 
779.6 > 323.1 40 25 
IMA 9.71 8 ESI+ [M+H]
+
 
494.3 > 394.0 45 35 
494.3 > 99.0 45 35 
IF 9.95 8 ESI+ [M+H]
+
 
261.1 > 183.0 35 20 
261.1 > 154.0 35 20 
CP 10.44 8 ESI+ [M+H]
+
 
261.1 > 140.0 30 25 
261.1 > 106.0 30 20 
ERL 10.53 8 ESI+ [M+H]
+
 
394.2 > 278.0 35 35 
394.2 > 336.1 35 25 
ETP 10.60 8 ESI+ [M+H]
+
 
589.0 > 229.0 55 15 
589.0 > 185.0 55 40 
DOX 11.39 9 ESI+ [M+H]
+
 
544.3 > 397.0 25 10 
544.3 > 130.0 25 15 
CAP 11.93 9 ESI+ [M+H]
+
 
360.2 > 244.1 25 10 
360.2 > 174.0 25 20 
OH-D-TAM 12.41 9 ESI+ [M+H]
+
 
374.3 > 223.0 35 15 
374.3 > 58.0 35 25 
OH-TAM 12.43 9 ESI+ [M+H]
+
 
388.3 > 72.0 40 30 
388.3 > 45.0 40 35 
TAM 13.74 10 ESI+ [M+H]
+
 
372.3 > 72.0 45 25 
372.3 > 45.0 45 30 
OH-PAC 13.93 10 ESI+ [M+H]
+
 
871.0 > 286.0 20 10 
871.0 > 526.0 20 25 
PAC 14.26 10 ESI+ [M+H]
+
 
854.5 > 105.0 20 40 
854.5 > 286.0 20 15 
CHL 15.34 11 ESI+ [M+H]
+
 
304.1 > 192.0 35 25 
304.1 > 168.0 35 35 
a
 Segment; 
b 
Values in bold correspond to the transitions used for quantification; 
c 
Collision energy. 
Table 3 
Determination coefficients (R
2
), repeatability (RSD), and limits of detection (LODs) and 
quantification (LOQ) obtained in the analysis of the target cytostatics by LC-ESI-MS/MS. 
 
Compound 
Linearity 
R
2
 
 RSD (%) LOD 
(ng mL
-1
) 
LOQ 
(ng mL
-1
)  50 ng mL
-1 
200 ng mL
-1 
5-Fu 0.9991  5.3 5.0 5.0 16.6 
Car-Pt 0.9972  4.7 4.4 2.5 8.3 
GEM 0.9982  2.3 2.3 0.6 2.0 
Oxa-Pt 0.9978  5.6 1.5 3.0 10.0 
MTIC 0.7481  32.9 30.2 7.4 24.7 
TMZ 0.9995  3.3 2.5 0.7 2.2 
MET 0.9918  1.4 1.6 0.7 2.2 
OH-MET 0.9983  3.3 3.1 0.9 2.9 
VCN 0.9963  5.6 5.9 10.3 34.3 
VBL 0.9924  6.1 1.4 7.5 25.0 
VRB 0.9943  4.8 4.5 8.3 27.6 
IMA 0.9917  4.8 2.4 8.0 26.7 
IF 0.9989  3.7 1.2 2.3 7.7 
CP 0.9978  2.0 1.3 0.1 1.7 
ERL 0.9940  4.1 3.7 0.1 1.0 
ETP 0.9963  4.1 5.0 9.0 30.0 
DOX 0.9943  1.3 3.6 0.8 2.5 
CAP 0.9996  2.1 1.8 0.6 1.9 
OH-D-TAM 0.9975  4.0 2.2 3.0 10.0 
OH-TAM 0.9961  1.7 1.8 1.5 5.0 
TAM 0.9976  2.8 1.9 5.0 16.7 
OH-PAC 0.9955  3.9 4.2 3.0 10.0 
PAC 0.9955  4.1 0.3 3.2 10.5 
CHL 0.9776  33.3 20.6 9.0 30.0 
 
 
 
 
Table 4 
Percentage of compound remaining in solution (HPLC water) after 24 hours at three different 
temperatures (4, 15 and 25ºC). 
Compound 4ºC 15ºC 25ºC 
5-Fu 101 100 89 
Car-Pt 107 85 71 
GEM 100 99 103 
Oxa-Pt 97 54 26 
MTIC 12 0.73 0.87 
TMZ 98 91 88 
MET 95 46 35 
OH-MET 86 - - 
VCN 98 96 93 
VBL 91 98 83 
VRB 101 105 104 
IMA 95 93 77 
IF 100 103 94 
CP 98 107 103 
ERL 96 101 100 
ETP 100 104 96 
DOX 89 90 77 
CAP 97 105 103 
OH-D-TAM 88 87 70 
OH-TAM 94 91 75 
TAM 88 - - 
OH-PAC 92 84 87 
PAC 89 72 78 
CHL 20 - - 
 
- not detected 
 
Table 5 
Stability of the compounds in HPLC water (with 4% DMSO) at different temperatures. 
 
Compound 
Temperature of storage 
25ºC 15ºC 4ºC -20ºC 
5-FU At least 1 day At least 1 day 1 month 3 months 
Car-Pt < 1 day At least 1 day 3 months 3 months 
GEM At least 1 day At least 1 day 2 months 3 months 
Oxa-Pt < 1 day < 1 day 6 days 1 month 
MTIC < 1 day < 1 day < 1 day < 1 day 
TMZ At least 1 day At least 1 day 2 months 3 months 
MET < 1 day < 1 day 6 days 1 month 
OH-MET < 1 day < 1 day 2 days 1 month 
VCN At least 1 day At least 1 day 2 months 2 months 
VBL At least 1 day At least 1 day 7 days 1 month 
VRB At least 1 day At least 1 day 2 months 3 months 
IMA < 1 day At least 1 day 3 days < 1 week 
IF At least 1 day At least 1 day 2 months 3 months 
CP At least 1 day At least 1 day 3 months 3 months 
ERL At least 1 day At least 1 day 3 days < 1 week 
ETP At least 1 day At least 1 day 3 months 2 months 
DOX < 1 day At least 1 day 3 days < 1 week 
CAP At least 1 day At least 1 day 3 months 3 months 
OH-D-TAM < 1 day At least 1 day 7 days 1 month 
OH-TAM < 1 day At least 1 day 9 days 1 month 
TAM < 1 day At least 1 day 5 days 1 month 
OH-PAC At least 1 day At least 1 day 3 days < 1 week 
PAC < 1 day < 1 day 3 days < 1 week 
CHL < 1 day < 1 day < 1 day < 1 day 
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